Same active ingredient. Not the same product. Branded GLP-1 is FDA-approved as finished drug, manufactured under cGMP, supplied in calibrated pen injectors. Compounded GLP-1 is prepared by licensed 503A or 503B pharmacies under federal exceptions; not FDA-approved as finished drugs.
Side-by-side
| Dimension | Compounded GLP-1 | Branded GLP-1 |
|---|---|---|
| Editorial score | 0/100 | 0/100 |
| Semaglutide | $145–$215/mo cash | $1,000+ list / $499+ NovoCare / $349+ Lilly Direct |
| Tirzepatide | — | — |
Who should pick Compounded GLP-1
Cash-pay patients (no coverage, high deductible, or excluded coverage); patients who want predictable low monthly cost; patients comfortable with the 503A/503B regulatory framework.
Who should pick Branded GLP-1
Patients with insurance coverage for branded at meaningful copay; patients who want FDA-approved labeling for indication-specific use (Wegovy CV, Zepbound OSA); patients who prefer the calibrated pen injector.
Frequently asked
Same ingredient — different products how?
Branded is FDA-approved finished drug. Compounded is prepared by 503A/503B pharmacies under federal exceptions. Same molecule; different manufacturing standards, excipients, container, and FDA approval status.
Are compounded legal?
Yes — when prepared by a licensed 503A pharmacy for individual patients with valid prescriptions, or by a 503B FDA-registered outsourcing facility under specific rules.
Will FDA make them illegal?
Bulk 503B production of sema/tirz has been phased out following shortage resolutions. Patient-specific 503A compounding continues. The category is regulated, not illegal.